Ciclesonide for the treatment of airway disease in horses

Abstract

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

Description

FIELD OF THE INVENTION[0001]The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids or inhaled glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).BACKGROUND INFORMATION[0002]Equine airway disease is a prominent disease in many horses. It can be divided into the diseases of the upper and lower airways. There are a number of equine lower airway diseases with noninfectious origin such as RAO (or heaves or equine chronic obstructive pulmonary disease), IAD, SPAOPD and exercise induced pulmonary hemorrhage (EIPH). The latter is typically diagnosed in racehorses. RAO, IAD and SPAOPD are discs eases with an allergic background. Rarely diagnosed ...

AI Technical Summary

Benefits of technology

[0007]In addition, the treatment option provided by the present invention minimizes the risks associated with complications caused by altered metabolism or compromised immune system, etc. Neutrophilia and lymphopenia is commonly observed after the state of the art treatment with dexamethasone (see example 4, Table 2). This can lead to increased susceptibility to infections. In contrast, no alteration is observed in the immune system of horses measured by neutrophilia and lymphopenia after treatment for two weeks with different dose levels of ciclesonide (see example 4, Table 2).

[0008]Another advantage of the present invention is treatment convenience. The state of the art treatment with dexamethasone does not allow the administration of constantly high dose levels for a longer time period due to the risk of developing side effects. Therefore, the dose of dexamethasone has to be continuously adjusted after treatment initiation considering a number of factors (e.g. route of drug administration, medical history, clinical condition and body weight of the horse) with the aim to prevent or minimize side effects while administering a high enough dose for assuring clinical efficacy. In contrast, the present invention provides a superior treatment option for horses with a lower risk for developing side effects. Thus, it does allow for a treatment over long periods of time at is constantly high dose levels with assuring the required clinical efficacy, which is comparable to dexamethasone.

[0009]Furthermore, the safety profile of ciclesonide is also more advantageous compared to other aerosol glucocorticoids like fluticasone proprionate. There are conflicting reports about the effect of fluticasone proprionate on cortisol levels. In some studies fluticasone proprionate shows significant suppression in measured cortisol levels in both humans and horses after aerosol administration (Robinson et al., 2009 and Grahnen et al., 1997). In contrast, there is no or clinically not relevant cortisol suppression with ciclesonide in humans or in horses after aerosol inhalation.

[0010]An additional advantage of the present invention is the prodrug nature of ciclesonide. It has been shown that the active metabolite, C21-C21-desisobutyrylciclesonide, is generated in the airways of humans or other mammals. The prodrug ciclesonide has to be activated by special enzymes in the airway tissues in order to generate C21-21-desisobutyrylciclesonide, which is the effective molecule. The existence of such special enzymes in the equine airway tissues has not been previously reported. Other substances like fluticasone proprionate, which is not a prodrug, do not need enzymatic conversion to be able to be active in the lungs of horses or other mammals. The present invention surprisingly demonstrates for the first time that ciclesonide can be converted into the effective molecule C21-C21-desisobutyrylciclesonide in horses (please see example 5) and that ciclesonide administration thus results in a beneficial therapeutic effect in horses with airway disease.

[0011]Furthermore, ciclesonide undergoes reversible fatty acid esterifications with fatty acids in human lung tissue. The fatty acid conjugates may serve as a depot. It has not been previously reported whether the same esterification process occurs in equine lung tissues as well or not. Other substances like fluticasone proprionate do not generate fatty acid conjugates in human lung tissues at all.

[0012]Therefore, even if large amounts of ciclesonide are swallowed during aerosol treatment the prodrug nature of ciclesonide, the dependency of C21-C21-desisobutyrylciclesonide generation on specific enzyme conversion and a quick liver metabolism of C21-C21-desisobutyrylciclesonide assures that the effect of ciclesonide is only related to the airways and not to the whole body of the horses. This is also referred to as topic effect of ciclesonide. In contrast, the state of the art treatment with dexamethasone or other substances like fluticasone leads to a systemic exposure of the active metabolite, leading to an extensive side effect profile.

Problems solved by technology

This can lead to increased susceptibility to infections.

The state of the art treatment with dexamethasone does not allow the administration of constantly high dose levels for a longer time period due to the risk of developing side effects.

Images